Inactive Instrument

Arcturus Therapeutics Ltd Share Price Nasdaq

Equities

IL0011280240

Biotechnology & Medical Research

Sales 2024 * 147M 11.72B Sales 2025 * 241M 19.22B Capitalization 717M 57.13B
Net income 2024 * -68M -5.42B Net income 2025 * 3M 239M EV / Sales 2024 * 2.4 x
Net cash position 2024 * 364M 29.01B Net cash position 2025 * - 0 EV / Sales 2025 * 2.97 x
P/E ratio 2024 *
-10.2 x
P/E ratio 2025 *
-154 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 91.25%
More Fundamentals * Assessed data
Dynamic Chart
Arcturus Therapeutics Holdings Insider Sold Shares Worth $610,574, According to a Recent SEC Filing MT
Arcturus Therapeutics Holdings Insider Sold Shares Worth $299,839, According to a Recent SEC Filing MT
Transcript : Arcturus Therapeutics Holdings Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 11:45 AM
Canaccord Genuity Adjusts Arcturus Therapeutics Holdings' PT to $87 From $81, Maintains Buy Rating MT
Wells Fargo Adjusts Price Target on Arcturus Therapeutics Holdings to $58 From $45, Maintains Overweight Rating MT
Transcript : Arcturus Therapeutics Holdings Inc., Q4 2023 Earnings Call, Mar 07, 2024
Arcturus Therapeutics Swings to Q4 Net Loss, Revenue Drops MT
Earnings Flash (ARCT) ARCTURUS THERAPEUTICS HOLDINGS Reports Q4 Revenue $34M, vs. Street Est of $37.9M MT
Arcturus Therapeutics Holdings Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Arcturus Therapeutics Holdings Inc. Announces Executive Changes CI
Arcturus Gets European Orphan Medicinal Product Label For ARCT-032 to Treat Cystic Fibrosis MT
Citigroup Raises Price Target on Arcturus Therapeutics to $48 From $40, Maintains Buy Rating MT
Transcript : Arcturus Therapeutics Holdings Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 03:00 PM
Passport Technologies, Inc. Commences Collaborative Research with Arcturus Therapeutics to Evaluate Transdermal mRNA Delivery Systems CI
CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster CI
More news
Managers TitleAgeSince
Chief Executive Officer 52 28/02/13
Director of Finance/CFO 59 31/08/19
Chief Operating Officer 45 31/12/12
Members of the board TitleAgeSince
Director/Board Member 83 31/08/19
Director/Board Member 65 26/05/18
Chairman 81 26/05/18
More insiders
Arcturus Therapeutics Holdings Inc. is a global messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose level. It is leveraging its LUNAR platform and its nucleic acid technologies to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and rare genetic disorders with significant unmet medical needs. Its COVID-19 vaccine candidate, which is based on its STARR technology platform is through Phase II clinical trials.
Calendar
Related indices
More about the company